Skip to main content
OpenTrials
Completed

NCT Number: NCT02367287

USDA Western Human Nutrition Research Center (WHNRC) Cross-Sectional Nutritional Phenotyping Study

Although the diet of the US population meets or exceeds recommended intake levels of most essential nutrients, the quality of the diet consumed by many Americans is sub-optimal due to excessive intake of added sugars, solid fats, refined grains, and sodium. The foundations and outcomes of healthy vs. unhealthy eating habits and activity levels are complex and involve interactions between the environment and innate physiologic/genetic background. For instance, emerging research implicates chronic and acute stress responses and perturbations in the Hypothalamic-Pituitary-Adrenal axis in triggering obesity-promoting metabolic changes and poor food choices. In addition, the development of many chronic diseases, including cardiovascular disease, diabetes, cancer, asthma and autoimmune disease, results from an overactive immune response to host tissue or environmental antigens (e.g. inhaled allergens). A greater understanding is needed of the distribution of key environment-physiology interactions that drive overconsumption, create positive energy balance, and put health at risk.

Researchers from the United States Department of Agriculture (USDA) Western Human Nutrition Research Center are conducting a cross-sectional "metabolic phenotyping" study of healthy people in the general population. Observational measurements include the interactions of habitual diet with the metabolic response to food intake, production of key hormones, the conversion of food into energy: the metabolism of fats, proteins, and carbohydrates, characteristics of the immune system, stress response, gut microbiota (bacteria in the intestinal tract), and cardiovascular health. Most outcomes will be measured in response to a mixed macronutrient/high fat challenge meal.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

USDA, Western Human Nutrition Research Center

Davis, California, 95616, United States

About this study

Many inflammatory responses can be modulated by specific dietary components. For example, in cardiovascular disease, macrophages and T-cells react with oxidized LDL (an endogenous modified antigen) to produce arterial plaque and subsequent blockage of coronary arteries. High intake of saturated fats (or simple sugars that drive synthesis of saturated fatty acids) may promote this inflammation by affecting macrophages and T-cells. Conversely, increased intake of omega-3 fatty acids may decrease inflammation by suppression of macrophage and T-cell pro-inflammatory activity. Long-term sub-clinical inflammation caused by intestinal bacteria has been linked to the development of Irritable Bowel Disease and related disorders. Low intake of fruits, vegetables, or whole grains or high intake of saturated fats may promote sub-clinical gut inflammation by promoting dysbiosis of the gut microbiota. Allergic asthma develops in predisposed individuals as a result of an overactive allergic-type immune response to inhaled environmental allergens. Dietary factors such as vitamin D and omega-3 fatty acids may diminish pro-inflammatory responses to environmental allergens by promoting the development of T-regulatory cells and other anti-inflammatory factors.

Individual variability in chronic disease risk is well recognized. For example, why does excess adiposity lead to disease in some individuals and not others? The nature of the fat tissue rather than the abundance, may impact cross-talk with other metabolically-relevant tissues and affect disease risk. It is important to characterize healthy vs. unhealthy phenotypes across various tissues and to understand how micro- and macro-nutrients interact with molecular and metabolic pathways to support a healthy body weight. This study brings together scientists with expertise in nutritional sciences, immunology, analytical chemistry, physiology, neuroendocrinology, and behavior to understand how diet impacts metabolism and disease risk through the interplay and coordination of signals and metabolites arising from multiple organ systems.

The overall objective is to characterize the phenotypic profile of participants according to their immunologic, physiologic, neuroendocrine, and metabolic responses to a dietary challenge and a physical fitness challenge by addressing the specific aims listed below. The cross-sectional study is organized into two study visits (Visit 1 and Visit 2) separated by approximately two weeks of at-home specimen and data collection.

Specific Aim 1: To determine if diet quality is independently associated with systemic immune activation, inflammation, or oxidative stress differentiated by:

  • pro-inflammatory T-helper cells (Th1, Th2, and Th17 cells) and related cytokines
  • anti-inflammatory T-regulatory cells and related cytokines
  • dysbiosis of the gut microbiota and markers of gut inflammation (e.g. neopterin and myeloperoxidase)

a. and to evaluate the association between dysbiosis of the gut microbiota, gut inflammation, and systemic immune activation

  • plasma metabolomic response to a mixed macronutrient challenge meal (includes diet quality and physical activity as independent variables)
  • endothelial (dys)function and vascular reactivity

Specific Aim 2: To determine if a high fat/sugar challenge meal induces differential effects over time (0-6h postprandial) according to habitual diet characteristics, physical activity levels, stress levels, age, sex, or BMI on:

  • postprandial monocyte activation
  • plasma lipid metabolomic responses including non-esterified fatty acids, phospholipids, triacylglycerols, red blood cell fatty acids, endocannabinoids, bile acids, eicosanoids and related oxylipins, ceramides, sphingoid bases, and acylcarnitines
  • plasma amino acid metabolomics
  • glucose metabolism and metabolic flexibility (i.e. the ability to switch from glucose to lipid oxidation as energy sources)
  • changes in endocrinology and self-report of hunger and satiety
  • postprandial free cortisol

Specific Aim 3: To determine the mechanisms of:

  • postprandial monocyte activation
  • suppression of challenge-meal induced monocyte activation by docosahexaenoic acid (DHA) (in an ex vivo experiment using a subset of samples)

Specific Aim 4: To evaluate the associations between eating behavior, physical activity, and/or anthropometry and the outcomes:

  • endocrinology of hunger and satiety
  • plasma metabolomic responses
  • vulnerability and resistance to stress
  • endothelial (dys)function and vascular reactivity
  • prediction of insulin sensitivity

Specific Aim 5: To determine how genetic variants affect nutrient metabolism, cardiovascular physiology, and immune function and improve understanding of how dietary factors affect these metabolic, cardiovascular and immune phenotypes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-65 y
  • Male or female
  • Body Mass Index 18.5-45.0 kg/m2 (Normal to obese)

Exclusion criteria

  • Pregnant or lactating women
  • Known allergy to egg-white protein
  • Systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg measured on three separate occasions
  • Diagnosed active chronic diseases for which the individual is currently taking daily medication, including but not limited to:
  • Diabetes mellitus
  • Cardiovascular disease
  • Cancer
  • Gastrointestinal disorders
  • Kidney disease
  • Liver disease
  • Bleeding disorders
  • Asthma
  • Autoimmune disorders
  • Hypertension
  • Osteoporosis
  • Recent minor surgery (within 4 wk) or major surgery (within 16 wk)
  • Recent antibiotic therapy (within 4 wk)
  • Recent hospitalization (within 4 wk)
  • Use of prescription medications at the time of the study that directly affect endpoints of interest (e.g. hyperlipidemia, glycemic control, steroids, statins, anti-inflammatory agents, and over-the-counter weight loss aids)

Treatment and study plan

Primary outcomes

  1. Baseline level and change in systemic immune activation following challenge meal

    Time frame: 0, 0.5, 3, and 6 hours postprandial

    Number and activation level of pro-inflammatory T-helper (Th) cells (Th1, Th2 and Th17), T-regulatory (Treg) cells, and B cells will be measured in fasting blood. Monocytes and neutrophils will be measured in fasting and postprandial blood.

  2. Baseline level and change in plasma metabolome

    Time frame: 0, 0.5, 3, and 6 hours postprandial

    Plasma fatty acid profiles of non-esterified fatty acids, phospholipids, triacylglycerols, red blood cell fatty acids, endocannabinoids, bile acids, eicosanoids and related oxylipins, ceramides, sphingoid bases, acylcarnitines, amino acids and other metabolites measured in response to a challenge meal.

Secondary outcomes

  1. Baseline level and change in glucose metabolism

    Time frame: 0, 0.5, 3, and 6 hours postprandial

    Glucose and insulin measured in response to a challenge meal.

  2. Baseline level and change in appetitive hormones

    Time frame: 0, 0.5, 3, and 6 hours postprandial

    Cholecystokinin, incretins, Peptide YY 3-36, ghrelin measured in response to a challenge meal.

  3. Baseline level and change in mitogen activated protein (MAP) kinase activity

    Time frame: 0, 0.5, 3 and 6 hours postprandial

    Mononuclear cells or B cells will be measured for MAP kinase activities in fasting and postprandial blood.

  4. Baseline level and change in dietary-responsive, circulating microRNA

    Time frame: 0, 0.5, 3, and 6 hours postprandial

    Plasma microRNA measured in response to a challenge meal

  5. Baseline level and change in RNA transcriptome

    Time frame: 0, 3, and 6 hours postprandial

    Transcriptome RNA sequenced in whole blood

  6. Genome Wide Association Study (GWAS)

    Time frame: 0 hours (fasting)

    DNA sequence from whole blood will be analyzed

  7. General health

    Time frame: 0 hours (Fasting)

    Clinical chemistry panel and complete blood count

  8. Anthropometrics

    Time frame: single time point

    Height (cm), weight (kg), waist and hip circumference (cm)

  9. Vital signs

    Time frame: single time point

    Blood pressure (mmHg), pulse rate (beats per minute) and temperature (degrees F).

  10. Body composition

    Time frame: single time point

    Body composition (percent body fat) and bone mineral density by Dual energy X-ray Absorptiometry scan.

  11. Resting and change in metabolism

    Time frame: 0, 0.5, 3, and 6 hours postprandial

    Resting and postprandial metabolic rates, including respiratory exchange ratios.

  12. Gut microbiota

    Time frame: single time point

    Gut microbiota composition and gene content will be assessed in stool using polymerase chain reaction (PCR) and sequencing

  13. Gut microbiota fermentation capacity

    Time frame: single time point

    The fermentation capacity of microbiota will be measured from a single stool sample

  14. Gut microbiota pathogen resistance capacity

    Time frame: single time point

    The pathogen resistance capability of microbiota will be measured from a single stool sample

  15. Gut inflammation

    Time frame: single time point

    Gut inflammation will be assessed by measuring molecules in stool and/or the response of intestinal epithelial cell cultures to fecal waters from a single stool sample.

  16. Stool metabolites

    Time frame: single time point

    Volatile and short chain fatty acids and bile acids will be measured in a single stool sample.

  17. Stool RNA markers

    Time frame: single time point

    RNA markers will provide a measure of genes expressed by cells of the colon naturally present in a single stool sample

  18. Baseline and change in hunger and appetite

    Time frame: 0, 1, 2, 3, 4, 5, and 6 hours postprandial

    Perceived hunger and fullness will be measured using a visual analog scale. Responses will be a marked on an unsegmented line from 0 or "not at all" to 5 or "extremely."

  19. Baseline and change in gut fermentation profile

    Time frame: 0, 1, 2, 3, 4, 5, and 6 hours postprandial

    Breath hydrogen and methane measured in response to a challenge meal.

  20. Recent dietary intake

    Time frame: Three 24-hour dietary recalls collected at home

    Random selection of 2 week days and 1 weekend day for 24-hour recall using an automated multi-pass method

  21. Dietary intake

    Time frame: single time point

    Food frequency questionnaire (FFQ)

  22. Behavior assessment

    Time frame: single time point

    Chronic stress questionnaire, food choice questionnaires, and a food preference activity.

  23. Taste thresholds

    Time frame: single time point

    Sampling tastes of sweet, salty, and bitter solutions in comparison to water to determine threshold of taste detection.

  24. Skin reflectance

    Time frame: single time point

    Spectrophotometric measure of skin pigmentation for assessment of vitamin D status.

  25. Peripheral arterial tone

    Time frame: single time point

    Use of the EndoPAT system to measure blood vessel tone.

  26. Pulmonary function

    Time frame: single time point

    Forced expiratory lung volume test

  27. Pulmonary inflammation

    Time frame: single time point

    Pulmonary inflammation measured as exhaled nitric oxide (NO)

  28. Executive function

    Time frame: single time point

    Executive function will be assessed using Cambridge Neuropsychological Test Automated Battery (CANTAB) and Iowa Gambling Task

  29. Cognitive function

    Time frame: single time point

    Measured by Wechsler Abbreviated Standard Intelligence test.

  30. Aerobic fitness assessment

    Time frame: single time point

    Pulse rate (bpm) and recovery after a 3 min YMCA Step Test

  31. Submaximal oxygen consumption

    Time frame: single time point

    The submaximal volume of oxygen consumed during a 4 minute treadmill walking protocol (VO2max) (ml/kg*min)

  32. Physical activity

    Time frame: daily, for 7 days

    Use of an accelerometer worn on the hip for 7 days

  33. Usual physical activity

    Time frame: single time point

    Activity recall using a questionnaire

  34. Heart rate variability and autonomic nerve conductivity

    Time frame: single time point

    Monitoring of autonomic balance, cardiac performance, and respiratory measurements and activity using MindWare Mobile Impedance Cardiograph.

  35. Allostatic Load

    Time frame: single time point

    An aggregate score derived from measures of urinary cortisol, norepinephrine, epinephrine, blood cholesterol, high sensitivity c-reactive protein, and hemoglobin A1C.

  36. Baseline and change in salivary cortisol in response to test meal

    Time frame: 0, immediately post-prandial, 30, 60, and 90 minutes post-prandial

    Salivary cortisol measured by enzyme-linked immunosorbent assay (ELISA)

  37. Baseline and change in salivary cortisol in response to exercise

    Time frame: 0, immediately post-exercise, 30, 60, and 90 minutes post-exercise

    Salivary cortisol measured by enzyme-linked immunosorbent assay (ELISA)

  38. Baseline and change in salivary cortisol in response to emotional recall task

    Time frame: 0, immediately post-task, 30, 60, and 90 minutes post-task

    Salivary cortisol measured by enzyme-linked immunosorbent assay (ELISA)

  39. Baseline and change in breath aldehydes

    Time frame: 0, 1, 4 and 6 hours postprandial

    The concentration of aldehydes present in human breath before and after a high-fat meal will be measured by mass spectrometry

Sponsors and collaborators

Lead sponsor

USDA, Western Human Nutrition Research Center

Fed

Registry information

Official study title

Assessing the Impact of Diet on Inflammation in Healthy and Obese Adults in a Cross-Sectional Phenotyping Study

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Feb 20, 2015
Registry last updated
Mar 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.